
    
      To evaluate the safety and efficacy of 4 doses of VCL-HB01, a therapeutic HSV plasmid DNA
      vaccine formulated with VaxfectinÂ® in HSV-2-seropositive adults with a reported history of
      symptomatic genital herpes for at least one year.
    
  